Media

2ND DRUG DEVELOPMENT FORUM   EXECUTIVE-LEVEL NETWORKING FOR BETTER COLLABORATION, MORE EFFECTIVE FUNDING STRATEGIES & MORE PRODUCTIVE R&D   SEPTEMBER 25-27, 2017 | RENAISSANCE BOSTON WATERFRONT HOTEL   NETWORK WITH

This Summit is focused on Cancer Immunotherapy, the most promising new cancer treatment approach since the development of the first chemotherapies. This summit brings together leading industry professionals in order

http://www.immuno-oncologysummit.com/ The Immuno-Oncology Summit will return to Boston again this August 28-September 1 with the goal of supporting researchers in developing the next generation of immunotherapies. Immuno-oncology researchers are changing

PRECISION: LUNG CANCER JULY 25-26 2017 BOSTON USA A GLOBAL PHARMA R&D SUMMIT http://precisionlungcancer.com/            

On June 13, Immunomic Therapeutics Inc. (ITI) participated in the “Making a Name in Cancer Immunotherapy” webcast, hosted by Nature.com. Other participating companies included Isoplexis, Merus, and Actinium Pharmaceuticals, Inc.

Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions Due to Peanut Allergy   TOKYO, Dec. 20, 2016 /PRNewswire/ -- Astellas Pharma Inc.

Immunomic Therapeutics Inc. is looking forward to attending the annual BIO Convention in San Diego, California next week. The International BIO Convention brings together nearly 16,000 innovators and researchers from

Science and health innovation do not exist in a vacuum. The cultural, social and political climate can indeed have a profound effect on funding priorities, public acceptance of new technologies

June 12, 2017 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Sia Anagnostou, Senior Director of Corporate Development at Immunomic Therapeutics, Inc., will participate in a BioPharma Dealmakers webcast, sponsored in

Sunday, June 4, 2017, is National Cancer Survivors Day and we are celebrating those who have defeated cancer and supporting patients who are currently fighting the disease. Over the past

By Colin Magowan A new interest has emerged on the CD4+ helper T cell and its role in anti-tumor responses. This renewed focus on the importance of this cell population

Bill Hearl and Greg Simon to Examine Lessons from the Cancer Moonshot Initiative    May 23, 2017 08:00 AM Eastern Daylight Time WASHINGTON--(BUSINESS WIRE)-- Tomorrow, IVY and Immunomic Therapeutics, Inc. (ITI)